Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice. by Nemoto, R. et al.
Br.J.Cancer(1993), 67, 893-897 © Macmillan Press Ltd., 1993
Inhibition by a new bisphosphonate (YM175) of bone resorption induced
by the MBT-2 tumour of mice
R. Nemotol, Y. Nishijima2, K. Uchida2 & K. Koiso2
'The Department of Urology, Tottori University School ofMedicine, Yonago 683, and 2The Institute ofClinical Medicine,
University of Tsukuba, Ibaraki 305, Japan.
Summary A new bisphosphonate, disodium dihydrogen (cycloheptylamino) methylene bisphosphonate mono-
hydrate (YM175), was compared with 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (AHPrBP) and
l-hydroxyethylidene-1,1-bisphosphonate (HEBP) in terms of its effect on tumour induced osteolysis using a
bladder tumour in mice (MBT-2). The method consisted of inoculating tumour cells subcutaneously (SC) over
the calvaria in mice, resulting in a local tumour causing fragmentation of the bone. The compounds were
active not only when administered preventively before establishment of bone resorption, but also in an
inhibitory fashion once the variables were already under the influence of the tumour. This osteolysis was
evaluated by measuring the increased area of bone resorption in reduced opacity to radiograph and histology.
The results showed the following sequence of potency: YM175 >AHPrBP = HEBP. This inhibition was
obtained with no apparent effect on the growth of the MBT-2 tumour. YM175 appears to be an interesting
new bisphosphonate with possible clinical application.
There are at least two mechanisms for osteolysis that occurs
in both human metastases and experimental skeletal metasta-
sis; osteoclast mediated bone destruction and direct destruc-
tion of bone independent of osteoclasts (Galasko & Bennett,
1976). Thus, agents that inhibit bone resorption might be
used to decrease the extent of bone destruction by the
tumour. Based on their action on calcium phosphate crystal
formation and on bone resorption, bisphosphonates repre-
sent a new class of drugs with considerable therapeutic
potential for metastatic bone disease (Fleisch et al., 1969;
Fleisch & Felix, 1979; Fleisch, 1983). Inhibition of tumour
induced osteolysis by bisphosphonates has been noted in
animal and human studies (Jung et al., 1981; VanHolten-
Verzantvoort et al., 1987; Morton & Howell, 1988).
With regard to experimental model systems of neoplasm-
associated local osteolysis, tumour-bone interactions using
calvaria of the mice were extensively studied by our group
(Nemoto et al., 1986; Nemoto et al., 1987; Nemoto et al.,
1988a; Nemoto et al., 1988b). In one of the recent studies,
suggestive evidence was obtained that our system might be
suitable for studying the biology of local interaction between
bone and cancer cells. Furthermore, it is suggested that bone
destruction induced by tumour cell invasion involves at least
two mechanisms; osteoclast mediated bone destruction, and
direct destruction of bone independent of osteoclasts. Bis-
phosphonate makes bone less susceptible to the action of
both osteoclasts and tumour cells (Nemoto et al., 1992).
In this paper, a new more powerful bisphosphonate,
YM175 was investigated and compared to both AHPrBP and
HEBP using as a model of osteolysis induced by MBT-2
tumour in mice and human prostate cancer cells in nude
mice.
Materials and methods
Animals
Female C3H/He mice, 8 to 12 weeks old, were purchased
from Clea Japan, Tokyo. Male BALB/c-nu/nu nude mice,
aged 8-12 weeks, were obtained from Clea Japan Inc.,
Tokyo, and were housed in standard cages fitted with filter
tops and handled in laminal flow hoods. They were fed
standard irradiated mouse diet and sterile water ad libitum.
Tumours
The tumour utilised in this experiment originated as an
invasive transitional cell carcinoma in an inbred C3H/He
female mouse having ingested the bladder carcinogen FANFT
for 11 months. This tumour, designated MBT-2, was orig-
inally provided by Dr M.S. Soloway and has been serially
transplanted in syngenic mice (Soloway, 1977). The tumour
has retained the histologic appearance of a poorly
differentiated transitional cell carcinoma. TSU-PRI is a cell
line derived from a primary adenocarcinoma of the prostate
in a 73-year-old man with multiple osteoblastic bone metas-
tases (Nemoto et al., 1988b).
Induction ofosteolysis
MBT-2 cells were transplanted routinely by subcutaneously
(SC) inoculation into female C3H/He mice. When the result-
ing tumour was visible, it was excised aseptically and minced
in medium 199. The tumour mince was further disrupted by
repeated syringing. A cell suspension containing 106 tumour
cells in 0.2 ml medium was inoculated SC over the calvaria of
C3H/He mice under ether anaesthesia. The viability of
tumour cells were assessed by using trypan blue dye exclusion
test. As the tumour cells were inoculated, the needle was used
to scratch the bone, which disrupted the periosteum. The
same method was used for the induction of osteolysis in the
nude mice using TSU-PRI human prostate carcinoma.
Radiographic andmicroscopic examination
Tumour-bearing animals were killed under anaesthesia when
the tumour grew to cover the calvaria. Tumours were
measured with calipers, and the mean tumour diameter was
calculated from the equation (L + W) x 0.5, where L is the
major and W the minor diameter. The two diameters were
measured at right angles to each other. Mice with tumours
less than 1Omm in diameter were excluded from analysis.
The parietal bones with attached tumour transplants were
fixed in buffered formaline and transferred to ethanol.
Radiographs were examined in blind conditions. The area of
bone resorption from radiograph detectable lesions was
measured by computerised analysis using graphtec software
for plotters. After decalcification by EDTA, the same sam-
ples were processed for histologic examination.
Treatment
The following bisphosphonates were used: YM175: disodium
dihydrogen (cycloheptylamino) methylene bisphosphonate
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monohydrate, AHPrBP: 3-amino-1-hydroxypropylidene-1,1-
bisphosphonate, and HEBP: 1-hydroxyethylidene-1, 1-bis-
phosphonate. YM175, HEBP and AHPrBP were synthesised
by the Department of Pharmacology, Medical Research
Laboratories, Central Research Laboratories, Yamanouchi
Pharmaceutical Co., Ltd. in Japan. Eel calcitonin (Sigma)
was dissolved in 0.05% NaCl and 0.2% sodium acetate in
distilled water containing 1 mg ml-' of bovine albumin (Sig-
ma). The bisphosphonates were dissolved in 0.9% NaCl solu-
tion and injected SC into the flanks. The doses and schedule
are specified in the tables and figures. Control animals were
given the solvent.
Statistical analysis
The data were analysed by one-way analysis of variance to
detect differences between groups. When difference were
detected (P<0.05), Fisher's multiple range test was used to
determine the significance. All values are presented as
mean ± s.d.
Results
If the tumour was not grown or not larger than 10 mm, the
mice were excluded from additional evaluation as judged by
radiography and histological examination.
The effects of various types of bisphosphonates and cal-
citonin on bone resorption induced by MBT-2 tumours in
mice assessed by graphtec software for plotters in radio-
graphs are presented in Table I. The inhibition rate (%) was
calculated from the equation (1-control/treated) x 100. Ani-
mals treated with the lower doses of YM175 (0.03 mg kg-')
showed weakened adhesion of tumours to skull and bone
perforation was infrequently observed. The radiograph detec-
table bone lesions showed significant reduction of osteolysis
(P<0.001). Furthermore, YM175 seemed to be remarkably
active when used in higher concentrations of 0.3 mg kg-'. All
bisphosphonates showed a clear dose-related effect. The least
active bisphosphonates were AHPrBP and HEBP. The most
active compound, YM175, was about more than ten times
more active than AHPrBP and HEBP. This inhibitory effect
on bone invasion by MBT-2 tumours was not accompanied
by a reduction of tumour growth. The mice tolerated the
injections well and there was no evidence of toxicity on the
basis ofbody weight, physical appearance or examination of
visceral organs. No effect on tumour induced osteolysis was
obtained with calcitonin.
The effect of YM175 on bone resorption induced by MBT-
2 tumours was influenced by the interval between drug injec-
tions (Table II). The administration of 0.3 mgkg-' of YM
175 every 3 days significantly reduced bone resorption (P<
0.01). Total dose of 6.0mgkg-' YM-175 was administered
by the interval of every 5 days (1.5 mgkg-' day-') and 10
days (3.0 mgkg-' day-'). The inhibitory effect was signifi-
cant.
The compounds were active not only when administered
preventively before the establishment of bone resorption, but
also when administered after the tumour began influencing
the bone (Figure la,b,c,d). Table III shows the effects of
YM175 injected 14 days after the induction of bone resorp-
tion using MBT-2 tumours. The lower concentration of
0.3 mgkg-' of YM175 significantly (P<0.05) suppressed
osteolysis when compared with the control mice sacrificed on
day 23. No effects on tumour induced osteolysis was ob-
tained with other drugs.
The radiographs show slight disconnection of the sagittal
suture of calvaria in the treated group in which osteolytic
lesions were scarce. Microscopic examinations revealed that
the sagittal sutures were divided by tumour invasion through
the connective tissue, not by the osteolytic activity.
The effects of various types of bisphosphonates and cal-
citonin on bone resorption induced by TSU-PR1 tumours in
nude mice assessed by graphtec software for plotters in
radiographs are presented in Table IV. The radiograph detec-
table bone lesions showed significant reduction of osteolysis
(P<0.001). All bisphosphonates showed a clear dose-related
effect as same as MBT-2 tumour induced osteolysis. No effect
on tumour induced osteolysis was obtained with calcitonin.
Table I Effect of various bisphosphonate on bone resorption induced by MBT-2 tumour in mice
Dose Body weight Tumour diameter Area of bone Inhibition
Group (n) (mgkg-') (g) (mm) resorption (mm2) rate (%)
Control(10) - 27.6 ± 1.5a 22.2 ± 2.8 36.0 ± 14.1
YM175(4)b 3.0 24.6 ± 0.9 22.6 ± 2.1 2.0 ± 1.od 94.5c
YM175(7) 0.3 26.0 ± 0.7 22.6 ± 2.1 11.3 ± 3.7d 68.7c
YM175(6) 0.03 28.8 ± 1.9 18.3 ± 1.6 16.2 ± 8.0d 55.0
AHPrBP(7) 3.0 24.6 ± 0.7 23.4 ± 1.9 16.0 ± 3.1d 55.6
AHPrBP(7) 0.3 25.2 1.4 23.3 1.9 28.8 ± 10.2 20.0
HEBP(5) 3.0 26.7 ± 2.6 22.6 ± 3.9 7.8 ± 6.1d 78.4 HEBP(6) 0.3 27.0 1.0 23.4 2.3 28.0 ± 6.5 22.3
Calcitonin(7) 3.0 25.6 ± 1.0 24.0 ± 1.0 31.7 ± 8.6 12.0
Calcitonin(6) 0.3 27.3 + 2.8 22.7 + 3.9 27.2 ± 13.5 24.5
aMean ± s.d. bDrugs were given from day 1 to completion of trial. cInhibition rate
(%) = (1-control/treated) x 100. dp<0.001 as compared to control animals.
Table II Effect of various dose intervals of YM175 on bone resorption induced by
MBT-2 tumour in mice
Body weight Tumour diameter Area of bone
Treatment(dose,n) (g) (mm) resorption (mm')
Control(6) 20.6 ± 1.0Oa 20.4± 4.9 34.7 ± 13.6
Interval between drug injections (day)b
1 (0.3 mg kg day,8) 20.4 0.9 21.4 3.0 9.0± 4.6c
3 (0.3mgkgday,7) 21.4 1.1 20.9±3.2 18.7±9.9d
5 (0.3mgkgday,6) 19.6 1.1 21.4±2.5 26.3+ 13.9
10 (0.3 mg kg day,8) 20.1 ±0.7 20.6 1.7 36.8 ± 16.0
5 (1.5 mg kgday,7) 20.0 1.3 19.7 2.3 9.7 2.4c
10 (3.0mg kgday,4) 20.0 1.8 17.5 4.7 15.3 6.9d
aMean ± s.d. bYM175 was given from day 1 to day 20. Mice were sacrificed day 22. CP<0.001 as compared to control animals. dp<0.01 as compared to control animals.TREATMENT OF TUMOUR-INDUCED OSTEOLYSIS 895
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Figure 1 Radiographs of mouse calvaria. a, Control without tumour growth, inoculated subcutaneously over the calvaria with
MBT-2 tumour cells after scratching the surface of the bone and sacrificed day 22. b, Non-treated control, inoculated sub-
cutaneously over the calvaria with MBT-2 tumour cells after scratching the surface of the bone and sacrificed day 14. Several
punched out lesions of the skull are shown. c, Nontreated control, inoculated subcutaneously over the calvaria with MBT-2 tumour
cells after scratching the surface of the bone and sacrificed day 22. Marked bone destruction is evident. d, Calvaria from mouse
treated with 3.0mg kg-' of YM175 from day 14 to day 21. Mice were sacrificed day 22. Osteolysis and punched out lesions are
suppressed as mice sacrificed day 14.
Table III Effect of YM175 on prior establishment of bone resorption induced MBT-2 tumour in
mice
Dose(n) Body weight Tumour diameter Area of bone
Group (mgkg-') (g) (mm) resorption (mm2)
Control
Sacrifice at day 14(11) 21.5 0.9a 9.3 3.9 23.4 11.9
Sacrifice at day 22(10) 21.8 1.1 20.8 5.0 53.6 14.1
YM175b
3.0mgkg-'(7) 21.8 1.1 22.1 4.4 27.3 10.8C
0.3 mgkg-'(6) 22.3 ± 0.8 21.8 ± 4.7 36.2 9.2d
AHPrBPb
3.0mgkg-'(6) 21.9 1.5 21.1 4.1 44.2 15.8
0.3 mgkg-'(4) 21.9 1.3 21.9 5.2 57.8 8.4
HEBPb
3.0mgkg-'(8) 21.6± 1.4 22.0 3.8 44.3 17.0
0.3 mgkg-'(7) 22.4 1.1 20.9 4.3 60.1 5.6
Calcitoninb
3.0 mgkg-'(5) 21.8 ± 0.8 19.3 ± 3.0 40.3 ± 24.6
0.3 mg kg-'(6) 21.1 1.7 21.2 4.1 53.2 10.6
aMean ± standard deviation. bDrugs were given from day 14 to completion of trial and mice were
sacrificed at day 22. CP<0.01 as compared with control animals. dp<0.05 as compared with control
animals.
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Table IV Effect of various bisphosphonate on bone resorption induced by human prostate cancer cell
in nude mice
Dose Body weight Tumour diameter Area of bone Inhibition
Group (n) (mg kg-') (g) (mm) resorption (mm) rate (%)
Control(8) - 24.6 ± 2.6a 23.9 ± 1.8 22.4 ± 9.5
YM175(4)b 0.3 25.6 ± 0.8 23.8 ± 2.3 3.4 ± 2.0' 84.8c
YM175(7) 0.03 26.1 ± 2.1 22.7 ± 2.4 7.1 ± 3.4d 68.3
AHPrBP(5) 3.0 25.7 ± 0.5 23.2 ± 1.5 7.0 ± 5.5d 68.7
AHPrBP(3) 0.3 24.0 ± 1.5 24.7 ± 3.2 9.0 ± 1.4d 59.8
HEBP(4) 3.0 25.0 ± 1.1 21.5 ± 3.2 4.3± 1.2d 80.8
HEBP(3) 0.3 25.2 ± 0.6 23.8 ± 1.4 12.6 ± 0.3c 48.0
Calcitonin(6) 3.0 24.3 ± 1.7 24.4 ± 2.2 12.2 ± 0.9 45.5
Calcitonin(5) 0.3 25.0 ± 2.7 26.1 ± 1.3 12.5 ± 1.4 44.2
aMean ± s.d. bDrugs were given from day 1 to completion of trial. clnhibition rate
(%) = (1-control/treated)) x 100. dP<0.001 as compared to control animals. 'P<0.01 as compared to
control animals.
Discussion
The course of malignant disease is often associated with
increased skeletal destruction and hypercalcemia. The efficacy
of new drugs capable of inhibiting bone resorption can be
assessed in several animal models of malignant osteolysis,
including the VX2 carcinoma in rabbits, the Walker 256/B
mammary carcinosarcoma and the prostate adenocarcinoma
in rats (Galasko & Bennett, 1976; Jung, 1984; Pollard &
Luckert, 1985). We established a model of tumour-induced
osteolysis using the MBT-2 tumour in mice (Nemoto et al.,
1986; Nemoto et al., 1987). Although it does not metastasise
to bone, the tumour does cause marked osteolysis. It has
been shown in the past that this model consists ofinoculating
MBT-2 tumour cells SC over the calvaria in mice, resulting
in a local tumour causing fragmentation of the bone, which
were evaluated by radiographic and histologic examination.
The present study was performed to test the effect of drugs
against tumour induced osteolysis using this model and it has
been found to respond to bisphosphonates. In order to quan-
titatively assess the changes induced by the compounds, a
method was developed to measure osteoclastic changes in
X-p film using an automatic image analyser. Animal models
have also been developed using human materials in this
system (Nemoto et al., 1988b).
Experiment evidence on YM175 indicated that it was
effective on hypercalcemia induced by parathyroid hormone
as well as parathyroid related hormone plus IL-lb in the rat
(Abe et al., 1989). This agent was also effective on osteolysis
induced by Walker carcinoma in rats (Kudo et al., 1990).
Our results clearly show that YM175 was effective in protec-
ting bone lysis induced by MBT-2 bladder tumours of mice.
This protection occurred without evidence of toxicity to the
animals and it did not interfere with tumour growth. All
three bisphosphonates tested, YM175, HEBP and AHPrBP,
showed a similar effect, namely, a powerful reduction of the
tumour-induced osteolysis as revealed by radiograph film and
microscopic examination. The new bisphosphonate, YM175,
displayed similar potency, but was more active than HEBP
and AHPrBP. With YM175, this inhibition of tumour in-
duced osteolysis was observed at a dose ten times lower than
the level where the maximum effect on resorption had occur-
red with the other two drugs.
This agent has not been tested in vivo on bone resorption
induced by human tumour cells. Our results show clearly that
YM175 was effective in protecting osteolysis induced by
human prostate cancer cells in nude mice. This protection
occurred without evidence or toxicity to the animals and no
interference with tumour growth.
In addition, other questions concerning the dose, the inter-
val, the route of administration and the duration of treat-
ment with bisphosphonates need to be answered. Little is
known about the efficacy of these compounds in the treat-
ment of established bone metastases.
It is interesting to notice that the administration of one
dose of YM175 was effective over a period of at least 5 days.
For HEBP and AHPrBP, this effect was comparable with
that obtained with daily injetions of 0.3 mgkg-' in MBT-2
tumour models. At these dosage levels, the effect was con-
trolled by adjusting the interval between drug injections.
The compounds were active not only when administered
preventively before the establishment of bone resorption, but
also when administered after the tumour began influencing
the bone. At present, the results suggest that osteolytic
lesions may be in remission for at least 10 days when treat-
ment with YM175 is halted. Further studies are needed to
elucidate the mechanism by which YM175 protects tumour
invasion of bones in this model.
The results of this study suggest the possibility of using
new, very powerful bisphosphonate in malignant bone di-
seases with progressive bone destruction. In addition, the
bisphosphonates may be administered for short periods or
adjusting the interval between drug injection. The drugs are
likely to be useful both in preventing the development of
bone disease and in treating established lesions. However,
further studies are required to determine the utility of this
compound in the clinical implication.
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